GlassScriptPhysician profile
Darshana Purohit
NPI 1346383031
$25,251.19
in general payments reported to CMS, 2019-2025
60 companies · $3,264 in 2025
The $3,264 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,071 · 2020: $1,451 · 2021: $3,600 · 2022: $7,940 · 2023: $2,865 · 2024: $3,059 · 2025: $3,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,127 · Education: $62.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,126.67 |
| Education | $62.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $4,915.76 | 2019-2025 | Afrezza |
| Lilly USA, LLC | $3,462.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $3,145.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,559.66 | 2019-2024 | Farxiga |
| Amneal Pharmaceuticals LLC | $1,429.13 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $1,129.28 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,118.72 | 2019-2025 | Jardiance, Synjardy |
| Cequr Corporation | $850.22 | 2022-2025 | Cequr Simplicity |
| Abbvie INC. | $707.28 | 2019-2025 | |
| Corcept Therapeutics | $620.81 | 2019-2025 | Korlym |
| Abbott Laboratories | $499.11 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Insulet Corporation | $482.62 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $458.77 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $449.94 | 2019-2025 | Evenity, Tepezza, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $401.88 | 2021-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $337.10 | 2019-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $307.76 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $242.57 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $206.72 | 2020-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $201.62 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $197.67 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $190.32 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Medtronic, INC. | $155.04 | 2021-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $140.60 | 2022-2025 | Strensiq |
| Ibsa Pharma INC. | $136.41 | 2019-2024 | Tirosint, Licart |
| Esperion Therapeutics, INC. | $119.71 | 2021-2025 | Nexletol |
| Astellas Pharma US INC | $108.83 | 2023-2025 | Veozah |
| Pfizer INC. | $105.94 | 2019-2025 | |
| Senseonics, Incorporated | $100.00 | 2019 | |
| Amarin Pharma, INC. | $99.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $99.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $97.80 | 2023-2024 | |
| Clarus Therapeutics INC. | $85.10 | 2021 | |
| Radius Health, INC. | $77.58 | 2020-2023 | Tymlos |
| Intuity Medical INC | $76.46 | 2022 | |
| Lifescan, INC. | $72.31 | 2022 | |
| Eusa Pharma (US) LLC | $72.26 | 2022 | |
| Endo Pharmaceuticals INC. | $68.48 | 2021-2023 | Aveed |
| Azurity Pharmaceuticals, INC. | $67.74 | 2022 | |
| Ascensia Diabetes Care US INC. | $64.11 | 2023 | |
| Becton, Dickinson and Company | $56.45 | 2021-2022 | |
| Vivus LLC | $48.68 | 2019 | |
| Acerus Pharmaceuticals Corporation | $48.53 | 2020-2021 | |
| Tolmar, INC. | $46.50 | 2024-2025 | Jatenzo |
| Sequel Med Tech, LLC | $44.80 | 2025 | Twiist |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.53 | 2019-2021 | |
| Horizon Therapeutics Plc | $36.61 | 2022-2023 | Tepezza |
| Rhythm Pharmaceuticals, INC. | $34.51 | 2025 | Imcivree |
| Acella Pharmaceuticals, LLC | $30.96 | 2025 | NP Thyroid 60 |
| Zealand Pharma US, INC. | $27.70 | 2022 | |
| Valeritas, INC. | $26.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.69 | 2024 | Crysvita |
| Embecta Corp. | $24.34 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Regeneron Healthcare Solutions, INC. | $19.52 | 2019 | |
| Ascendis Pharma Endocrinology INC | $15.53 | 2023 | |
| Vistapharm, INC. | $13.30 | 2021 | |
| Aytu Biopharma, INC. | $12.53 | 2019 | |
| Gilead Sciences, INC. | $12.35 | 2019 | |
| Companion Medical, INC. | $12.16 | 2020 | |
| Alfasigma USA, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshana Purohit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.